Navigation Links
Drug Proves Effective in Slowing Melanomas
Date:4/15/2008

Riluzole, used to treat Lou Gehrig's disease, inhibits aggressive growth, study finds

TUESDAY, April 15 (HealthDay News) -- The drug riluzole, approved in the United States to treat amyotrophic lateral sclerosis (ALS), slows the growth of highly aggressive melanoma skin cancer, according to a new study.

A common feature of both melanoma and ALS (also called Lou Gehrig's disease) is an excess amount of the protein glutamate, a cellular growth factor or food for cells. Too much glutamate can overstimulate neurons to the point where they burn out -- a possible explanation for what happens in ALS, according to background information in the study. Overproduction of glutamate causes the growth and expansion of melanoma.

Riluzole (brand name Rilutek) inhibits the release of glutamate.

In laboratory tests using cultures of human melanoma cell lines, researchers at Rutgers University and the Cancer Institute of New Jersey found that riluzole appeared to switch off overproduction of glutamate and slow the growth rate of the melanoma cells. In tests on animals, the drug showed the same suppression of melanoma cell growth.

The researchers then started testing the drug on 11 people with late-stage (stage 3 or 4) melanoma. The patients in this phase 0 (exploratory, first-in-humans) trial received riluzole for two weeks.

"Our preliminary results show three solid positive responses in nine of the patients who had been able to complete the trial to date," Dr. James Goydos, a surgical oncologist at the Cancer Institute of New Jersey, said in a prepared statement.

Other patients in the group showed some indications of responding to the drug, and they'll be reassessed at the end of the trial.

The research was to be presented April 15 at the annual meeting of the American Association for Cancer Research, in San Diego.

The findings provide "enough data to show that we should go on to a more extensive (phase 1/2) trial," Goydos said. He expects it will begin later this year and include 50 to 100 patients with stage 4 melanoma.

"I think this drug is going to be extremely important as an adjunct to surgical treatment of stage 3 or stage 4 melanoma," Goydos said. "The challenge is to keep it from recurring, which has happened in patients on the order of 50 percent. With low toxicity likely, riluzole could potentially be given for long periods of time to slow down the metabolic process responsible for the disease's recurrence."

More information

The U.S. National Cancer Institute has more about melanoma.



-- Robert Preidt



SOURCE: Rutgers University, news release, April 15, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. Nasal Anthrax Vaccine Proves Effective in Animal Study
3. FDA Approves New Roche West Nile Virus Blood Screening Test
4. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
5. Exercise and yoga improves quality of life in women with early-stage breast cancer
6. Toddler Study Proves Humans Outsmart Apes
7. Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals
8. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
9. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
10. FDA Approves SOMA(R) (carisoprodol) 250 mg
11. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... Specialty Technical Publishers ... International Audit Protocol Consortium (IAPC) EHS audit protocol for Great Britain . ... scope of their EHS regulatory obligations and rapidly collect, share, archive, and export ...
(Date:12/5/2016)... ... December 05, 2016 , ... What: Shriners Hospitals for Children, with ... to our patients – using a video monitor and web-enabled camera. Santa visits with ... the Auditorium into a Christmas Wonderland, which is where the video connection to the ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... it has been featured in SuperbCrew magazine, a leading online tech news platform ... This interview, now featured on SuperbCrew.com, explores the state of enterprise mobility security ...
(Date:12/5/2016)... ... December 05, 2016 , ... Progressive Laboratories™ is one ... glutathione to enhance production of nitric oxide (NO). , NitroGenesis Pro™ is made ... NO twice as effectively and sustains NO blood levels twice as long as ...
(Date:12/5/2016)... NY (PRWEB) , ... December 05, 2016 , ... Dr. ... 5th Avenue Cosmetic Plastic Surgery, who recently participated in the 36th Annual Cutting Edge ... five of the newest techniques for getting that perfect, yet natural-looking, nose. Dr. Weintraub, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... and BOCA RATON, Fla. ... Florida Institute for the Commercialization of Public Research ... has finalized a funding agreement SegAna, LLC, an ... developed at University of Central Florida. The Florida ... research, and bridges early funding gaps for companies ...
(Date:12/5/2016)... and PUNE, India , December 5, 2016 ... "Surgical Sutures Market by Product Type and by Application - Global Opportunity Analysis ... $3,360 million in 2015, and is expected to reach $5,255 million by 2022, ... dominated the market in 2015 with more than four-fifths share. ... ...
(Date:12/5/2016)... and Gateway Health proudly announce a dynamic collaboration that will ... members with specific high risk needs. In an ... of consumers, Wellbridge combines technology and population expertise with a ... daily behaviors and lifestyle. ... , , "Dealing ...
Breaking Medicine Technology: